AstraZeneca charts new course for Imfinzi in liver cancer, but FDA path remains uncertain

With the metastatic liver cancer field growing increasingly crowded for immunotherapies, AstraZeneca is trying to reach new ground with Imfinzi in locoregional disease. But a regulatory hurdle lies ahead before the company can blaze the trail.